Clinical Trials Directory

Trials / Completed

CompletedNCT00685477

Dose Response of Intravenous Sincalide(CCK-8) for Gallbladder Emptying

Dose Response of Intravenous Sincalide (CCK-8) for Gallbladder Emptying

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
60 (actual)
Sponsor
Temple University · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Accepted

Summary

This is a clinical research study to establish normal values for the infusion of a synthetic form of the hormone cholecystokinin(CCK-8) for gallbladder emptying. Cholecystokinin is released from the small bowel to stimulate the pancreas and gallbladder to help digest and absorb food. Some people have gallbladder problems and need to be tested with the synthetic cholecystokinin ( Kinevac®, Bracco Diagnostics, Inc.). The aim of this study is to find out how differing amounts and intravenous infusion times of CCK-8 affect gallbladder emptying. The findings in normal subjects will be used to establish normal values that can then be compared with patients with suspected gallbladder disease.

Detailed description

This study enrolled 60 healthy volunteers from four institutions (Johns Hopkins University, Pennsylvania State University, Memorial Health University Medical Center, and Temple University. Subjects had to be healthy men or women 18-65 years old with no gastrointestinal disease as confirmed by initial screening using a modified Mayo Clinic Research Gastrointestinal Disease Screening Questionnaire, and normal results for CBC, metabolic profile, serum amylase and gallbladder ultrasonography. Women could not be enrolled if pregnant. Subjects had 3 infusion studies at least 2 days apart within 3 weeks.

Conditions

Interventions

TypeNameDescription
DRUGExperimental Sequence ABCDrug will be given over 15 minutes, followed by infusion over 30 minutes, followed by infusion over 60 minutes
DRUGExperimental Sequence ACBDrug infused over 15 minutes, followed by infusion over 60 minutes, followed by infusion over 30 minutes
DRUGExperimental Sequence BACDrug will be given over 30 min infusion, followed by 15 minute infusion, followed by 60 minute infusion
DRUGExperimental Sequence BCADrug will be given over 30 min infusion, followed by 60 minute infusion, followed by 15 minute infusion
DRUGExperimental Sequence CABDrug will be given over 60 min infusion, followed by 15 minute infusion, followed by 30 minute infusion
DRUGExperimental Sequence CBADrug will be given over 60 min infusion, followed by 30 minute infusion, followed by 15 minute infusion

Timeline

Start date
2008-05-01
Primary completion
2009-05-01
Completion
2009-07-01
First posted
2008-05-28
Last updated
2017-02-17
Results posted
2017-02-17

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00685477. Inclusion in this directory is not an endorsement.